Who
Rebecca Taub
Director
Company insider
Files Form 4 as: Pres., R&D, and CMO, Madrigal Pharmaceuticals; SVP, Research & Development, VIA Pharmaceuticals.
In numbers
- Trades disclosed
- 181
- Buys
- 1
- Sells
- 18
- Bought
- $9,750
- Sold
- $100.7M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 15 Jan 2008
- Last trade
- 17 Jun 2026
- Last filed
- 18 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Jun 2026filed 18 Jun 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —454 at $0.00 | filing |
| 17 Jun 2026filed 18 Jun 2026 | MDGL Madrigal Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —766 at $0.00 | filing |
| 17 Jun 2026filed 18 Jun 2026 | MDGL Madrigal Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —766 at $0.00 | filing |
| 17 Jun 2026filed 18 Jun 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —454 at $0.00 | filing |
| 6 Mar 2026filed 6 Mar 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $212K491 at $431.94 | filing |
| 6 Mar 2026filed 6 Mar 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $212K491 at $431.94 | filing |
| 26 Jan 2026filed 26 Jan 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $319K647 at $492.42 | filing |
| 26 Jan 2026filed 26 Jan 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $319K647 at $492.42 | filing |
| 20 Jan 2026filed 20 Jan 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $1.1M2,238 at $490.77 | filing |
| 20 Jan 2026filed 20 Jan 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $1.1M2,238 at $490.77 | filing |
| 9 Jan 2026filed 13 Jan 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | $291K18,410 at $15.80 | filing |
| 9 Jan 2026filed 13 Jan 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $229K440 at $521.11 | filing |
| 9 Jan 2026filed 13 Jan 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $307K588 at $521.95 | filing |
| 9 Jan 2026filed 13 Jan 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $383K732 at $522.98 | filing |
| 9 Jan 2026filed 13 Jan 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $700K1,335 at $524.06 | filing |
| 9 Jan 2026filed 13 Jan 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $782K1,489 at $525.12 | filing |
| 9 Jan 2026filed 13 Jan 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $480K913 at $526.05 | filing |
| 9 Jan 2026filed 13 Jan 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $598K1,135 at $526.95 | filing |
| 9 Jan 2026filed 13 Jan 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $246K465 at $528.16 | filing |
| 9 Jan 2026filed 13 Jan 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $293K554 at $529.28 | filing |
News
Comparing Madrigal Pharmaceuticals (NASDAQ:MDGL) and Incyte (NASDAQ:INCY)MDGL · themarketsdaily.com · 20 Oct 2026Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)MDGL · manilatimes.net · 15 Oct 2026Madrigal Pharmaceuticals (NASDAQ:MDGL) & Coya Therapeutics (NASDAQ:COYA) Critical ContrastMDGL · themarketsdaily.com · 9 Oct 2026
0 headlines in the last 90 days name Rebecca Taub; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.